- Evaluating Effectiveness and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia in (CML-CP) without Optimal Response (Warning, Failure) to Imatinib or/and DasatinibLi Weiming; Zhang, Yanli; Wu, Zhiwei; Wen, Qin; Leng, Qing; Wu, Shuting; Wang, Xiaodong; Chen, Shiming; Yuan, Guolin; Qian, Sixuan; Chen, Suning; Jiang, Daozi; Diao, Lianjun; Xi, Zhenfang; Wu, Hui; Sun, Hui; Yang, Lijie; Wang, Hongjuan; Zhang, Xuefang; Xu, Yanli; Zhao, Xielan; Xu, Na; Meng, Li; Zhu, Zunmin; Zhao, Youfang; Su, Meifang; Yang, Zhuangzhi; Liu, Chuancai; Han, Danlei; Hu, Yu65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
- Flumatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: An OpenLabel, Multi-Center StudyWen, Ziyu; Zhao, Ying; Li, Guowei; Su, YongZhong; Chen, FeiHeng; Tao, HongFang; Zheng, ZhengJin; Lin, Wuqiang; Chen, Xiuli; Meng, Meili; Yu, Lian; Chen, LongTian; Huang, JianQing; Wu, Guocai; Zhao, Mengxia; Liu, Zhenfang; Zhu, Hongqian; Jiang, Yirong; Liu, Qifa; Liu, Xiaoli; Xu, Na65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
- Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid LeukemiaChen, Suning; Zhang, Yanli; Xu, Na; Sun, Hui; Li Weiming; Yang, Yunfan; Zhu, Zunmin; Duan, Minghui; Qian, Sixuan; Zhu, Yu; Luo, Jianmin; Wang, Xiaodong; Yang, Wei; Gu, Weiying; Li, Fei; Liu, Bingcheng; Xu, Yunxiao; Liu, Zhenfang; Wang, Chunling; Jiang, Yirong; Meng, Li; Wen, Qin; Xu, Yanli; Zou, Xingli; Wang, Wei; Xue, Yan; Xu, Hao; Bi, Kehong; Zhou, Fuling; Ma, Liangming; Fu, Rong; Ouyang, Guifang; Ding, Kaiyang; Wu, Depei65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
会议论文
Safety and Efficacy of Flumatinib in Patients with Chronic Myeloid Leukemia Resistant or Intolerant to Imatinib
9阅读
